TY - JOUR
TI - Serum bactericidal activity of three different dosing regimens of colistin with implications for optimum clinical use
AU - Daikos, G.L.
AU - Skiada, A.
AU - Pavleas, J.
AU - Vafiadi, C.
AU - Salatas, K.
AU - Tofas, P.
AU - Tzanetou, K.
AU - Markogiannakis, A.
AU - Thomopoulos, G.
AU - Vafiadi, I.
AU - Petrikkos, G.
JO - Journal of Chemotherapy
PY - 2010
VL - 22
TODO - 3
SP - 175-178
PB - Maney Publishing
SN - 1120-009X, 1973-9478
TODO - 10.1179/joc.2010.22.3.175
TODO - colistimethate, adult;  aged;  article;  bactericidal activity;  blood sampling;  clinical article;  concentration response;  controlled study;  dosage schedule comparison;  drug dose regimen;  female;  high performance liquid chromatography;  human;  male;  maximum plasma concentration;  minimum inhibitory concentration;  nonhuman;  optimal drug dose;  Pseudomonas aeruginosa;  serum
TODO - Although colistin methanesulfonate (CMS) has been used extensively in critically ill patients infected with multidrug-resistant organisms, the optimum dosing regimen remains to be determined. Herein, we examined the pharmacokinetics of three different dosing regimens of CMS, 3 million units every 8 h (regimen A), 4.5 million units every 12 h (regimen B), 9 million units every 24 h (regimen C) and evaluated the bactericidal activity of serum containing various concentrations of colistin against Pseudomonas aeruginosa with a minimum inhibitory concentration (MIC) of 1 μg/ml. The means ± SE serum Cmax of colistin for regimens A, B, and C were 3.34±0.35, 2.98±0.27, and 5.63±0.87 μg/ml, respectively. All serum samples containing colistin >4 μg/ml (serum concentration/MIC >4) eliminated P. aeruginosa whereas only 40% of samples containing colistin <4 μg/ml resulted in complete bacterial killing. These findings indicate that the currently used dosing regimens might not provide the most effective therapy with CMS and justify administering larger dosages in longer intervals. © E.S.I.F.T. srl.
ER -